



society of hematologic oncology

PRÉ-PROGRAMME

5ÈME ÉDITION 2026

CONGRÈS EN HÉMATOLOGIE
du 14 au 16 octobre 2026

SOBONNE UNIVERSITÉ
AUDITORIUM DU CICSU, 75005 PARIS



Mandatée par
l'association ARCADE

LE COMITÉ SCIENTIFIQUE



Présidente : **Mauricette MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)

- **Amine BELHABRI** (Hématologue, Centre Léon Bérard, Lyon)
- **Sylvain CHOQUET** (Hématologue, Hôpital Pitié-Salpêtrière, Paris)
- **Jean-Jacques KILADJIAN** (Hématologue, Hôpital Saint-Louis, Paris)
- **Xavier LELEU** (Hématologue, Centre Hospitalier Universitaire de Poitiers, Poitiers)
- **François-Xavier MAHON** (Hématologue, Institut Bergonié, Bordeaux)
- **Anne-Sophie MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)
- **Sophie PARK** (Hématologue, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble)
- **Christian RECHER** (Hématologue, Institut Universitaire du Cancer de Toulouse, Toulouse)
- **Philippe ROUSSELOT** (Hématologue, Centre Hospitalier de Versailles, Versailles)
- **Pierre SESQUES** (Hématologue, Centre Hospitalier Lyon Sud, Lyon)

Wednesday 14th october 2026

10h00 - 10h30 INTRODUCTION

10h30 - 11h45 SESSION 1: MYELOPROLIFERATIVE NEOPLASMS

Chair: Jean-Jacques KILADJIAN (Hematology, Paris)

- It moves in essential thrombocythemia!

Jean-Jacques Kiladjian, Hematology – Paris – 20min

- Skin carcinomas complicating treatments for NMPs

Hélène Pasquer, Hematology – Paris – 20min

- Contribution of AI in the NMP

Vincent Alcazer, Hematology – Pierre-Bénite – 20 min

- Discussion – 15 min

11h45 - 12h45 1st SYMPOSIUM

12h45 - 13h45 LUNCH BREAK & MEET OUR PARTNERS



13h45 - 15h00 SESSION 2 : MYELOYDYSPLASTIC SYNDROMES

Chair: Sophie PARK (Hematology, Grenoble)

- Management of clonal hematopoiesis in clinical practice : GFM recommendations

Aline Renneville, Pharmacy – Paris – 20 min

- Optimization of pre and post transplantation therapies in mds

Marie Robin, Hematology – Paris – 20 min

- How to treat CMML: should we target stem or differentiated cells ?

Raphael Itzykson, Hematology – Paris – 20 min

- Discussion – 15 min

15h00 - 15h30 CALL FOR ABSTRACT

15h30 - 16h30 2nd SYMPOSIUM

16h30 - 16h50 COFFEE BREAK & MEET OUR PARTNERS



16h50 - 17h20 ROUNDTABLE DISCUSSION : ACUTE MYELOID LEUKEMIA

17h20 - 18h35 SESSION 3: ACUTE MYELOID LEUKEMIA

Chairs: Amine BELHABRI (Hematology, Lyon) & Arnaud PIGNEUX (Hematology, Bordeaux)

- Functional Precision Medicine for acute myeloid leukemia

Raphael Itzykson, Hematology – Paris – 20 min

- BIG Experience in France: Results of BIG-1 and future BIG-2 program

Sarah Bertoli, Hematology – Toulouse – 20 min

- Results from PARADIGM study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Amine Fathi, Hematology – Boston (USA) – 20 min

- Discussion – 15 min

Thursday 15th october 2026

09h30 - 10h25 **SESSION 4: ACUTE LYMPHOBLASTIC LEUKEMIA**

Chair: Aurélie CABANNES (Hematology, Versailles)

- First results of the ALL TARGET observatory
Aurélie Cabannes, Hematology - Versailles - 15 min
- GRAALL recommendations for relapsed ALL
Marie Balsat, Hematology - Lyon - 15 min
- New development of immunotherapies in B-ALL
Nicolas Boissel, Hematology - Paris - 15 min
- Discussion - 15 min

10h25 - 10h45 **COFFEE BREAK & MEET OUR PARTNERS**



10h45 - 11h45 **3rd SYMPOSIUM**

11h45 - 12h55 **SESSION 5: CAR-T CELLS**

Chair: Pierre SESQUES (Hematology, Lyon)

- Estimating the real price of CAR-T cells in France: From list price to net price
Carole-Anne Brugère, Calym/Hematology - Lyon - 15 min
- Recommendations from the LYSA centered on the place of the CAR-T cells and data on the L2: comparison vs SOC & Axi-liso: sequence?
Benoît Tessoulin, Hematology - Nantes - 15 min
- Impact of T cell characteristics on CAR-T cell therapy / Fitness of T in the CAR-T cells? Present and future
Estelle Bourbon, Hematology - Lyon - 15 min
- MM : CAR-T cells then bispecific? bispecific then CAR-T cells? Upcoming sequence?
Alexis Talbot, Immuno-hematology - Paris - 15 min
- Discussion - 15 min

12h55 - 13h55 **LUNCH BREAK & MEET OUR PARTNERS**



13h55 - 14h55 **4th SYMPOSIUM**

14h55 - 16h05 **SESSION 6: MULTIPLE MYELOMA**

Chair: Xavier LELEU (Hematology, Poitiers)

- New HRMM score - Where are we at with the measurement of the non-MOM MRD
Anaïs Schavgoulidze, Medical biology - Toulouse - 15 min
- Response or resistance! based on interesting data from RESISTEC. Do we have a predictive response marker, is it useful for real life?
Ludovic Martinet, Research - Toulouse - 15 min
- NDMM TE and TI. The IT will replace the autograft, can you convince us?
Cyrille Touzeau, Hematology - Nantes - 15 min
- Tomorrow's IT, new ADCs, new CAR-T, Trispe. With the MAJESTEC 3 and TEC LILLE data, do we still need to develop always more, for what? what are the limits of current TTTs that justify developing more, whether it is safety, efficacy, or cost
Alexis Talbot, Immuno-hematology - Paris - 15 min
- Discussion - 15 min

16h05 - 16h20 **COFFEE BREAK & MEET OUR PARTNERS**



16h20 - 16h50 **CALL FOR ABSTRACT**

16h50 - 17h20 **SHORT-TALKS**

17h20 - 18h20 **SESSION 7: LYMPHOMAS**

Chair : Sylvain CHOQUET (Hematology, Paris)

- Intravascular NHL

Antoine Bonnet, Hematology – Nantes – 15 min

- Primary mediastinal NHL

Vincent Camus, Hematology – Rouen – 15 min

- Relapse/refractory Hodgkin lymphoma

Cedric Rossi, Hematology – Dijon – 15 min

- Discussion – 15 min

Friday 16th october 2026

10h00 - 11h15 **SESSION 8: CHRONIC MYELOID LEUKEMIA**

Chair : François-Xavier MAHON (Hematology, Bordeaux)

- Development of machine learning applied to CML: prognostic and predictive factors

Vincent Alcazer, Hematology – Pierre-Bénite – 20 min

- TBC

Franck Nicolini, Hematology – Lyon - 20 min

- Individualizing front line therapy of chronic phase CML

Delphine Réa, Hematology – Paris - 20 min

- Discussion – 15 min

11h15 - 11h30 **COFFEE BREAK & MEET OUR PARTNERS**



11h30 - 12h30 **5th SYMPOSIUM**

12h30 - 13h45 **SESSION 9: CELL THERAPY AND TRANSPLANTATION**

Follow up and treatments after allo-HSCT for hematological malignancies.

Chair: Anne HUYNH (SFGM-TC president) (Hematology and transplantation, Toulouse)

- Post allo-HSCT monitoring? - 20 min
- Prophylactic treatments after allo-HSCT - 20 min
- Treatments of relapse after allo-HSCT - 20 min
- Discussion – 15 min

13h45 - 14h45 **LUNCH BREAK & MEET OUR PARTNERS**



14h45 - 14h55 **AWARD CEREMONY - CALL FOR ABSTRACT**

14h55 - 15h10 **SHORT-TALK**

15h10 - 16h25 **SESSION 10: CHRONIC LYMPHOCYTIC LEUKEMIA**

Chair : Anne-Sophie MICHALLET (Hematology, Lyon)

- Should all patients be treated with a fixed duration of CLL as a first-line treatment?

Emmanuelle Ferrant, Hematology – Lyon – 20 min

- Is there hope for treating Richter syndrome with new innovative therapies?

Pierre Feugier, Hematology – Nancy – 20 min

- Is immunochemotherapy still the gold standard for first-line treatment in MW?

Cécile Tomowiak, Hematology – Poitiers – 20 min

- Discussion – 15 min

16h25 - 16h40 **TAKE HOME MESSAGE**